Cargando…
Salvage treatment with anlotinib for advanced non‐small cell lung cancer
BACKGROUND: This real‐world study assessed the efficacy and toxicity of anlotinib as salvage treatment in Chinese patients with advanced non‐small cell lung cancer (NSCLC). METHODS: The medical records of 81 patients with advanced NSCLC who had failed at least two lines of chemotherapy were retrospe...
Autores principales: | Wu, Di, Nie, Jun, Dai, Ling, Hu, Weiheng, Zhang, Jie, Chen, Xiaoling, Ma, Xiangjuan, Tian, Guangming, Han, Jindi, Han, Sen, Long, Jieran, Wang, Yang, Zhang, Ziran, Fang, Jian |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons Australia, Ltd
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6610258/ https://www.ncbi.nlm.nih.gov/pubmed/31183998 http://dx.doi.org/10.1111/1759-7714.13120 |
Ejemplares similares
-
A phase II study of anlotinib in 45 patients with relapsed small cell lung cancer
por: Wu, Di, et al.
Publicado: (2020) -
Efficacy and toxicities of gemcitabine and cisplatin combined with endostar in advanced thymoma and thymic carcinoma
por: Wang, Yang, et al.
Publicado: (2018) -
Evaluation of efficacy and toxicity of nivolumab combined with or without docetaxel in patients with advanced NSCLC
por: Wang, Yang, et al.
Publicado: (2021) -
Immune-Related Adverse Events and Their Association With the Effectiveness of PD-1/PD-L1 Inhibitors in Non-Small Cell Lung Cancer: A Real-World Study From China
por: Chen, Xiaoling, et al.
Publicado: (2021) -
Pembrolizumab or Bevacizumab Plus Chemotherapy as First-Line Treatment of Advanced Nonsquamous Nonsmall Cell Lung Cancer: A Retrospective Cohort Study
por: Zhang, Jie, et al.
Publicado: (2021)